July 3, 2020

Vicore Pharma has completed a directed share issue of SEK 185 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED ...
Read more
July 2, 2020

Vicore Pharma intends to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, , CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE U...
Read more
July 2, 2020

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

Paris, France, July 2, 2020, 5.45 pm CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing...
Read more
July 2, 2020

Invitation to attend a teleconference on July 2, 1.30 pm CET – DTx US commercialization plan

Uppsala, Sweden – July 2, 2020 – Due to today´s announcement the US launch of deprexis® and vorvida® has been initiated and the decision to accelerate the launch of the com...
Read more
July 2, 2020

Orexo launches deprexis® and vorvida® in the US and provides updated financial guidance

FDA´s “Enforcement Policy” and Orexo´s strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies ...
Read more
July 1, 2020

Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome

Company Expects to Report Topline Phase 3 LOGICS Study Results During the Third Quarter of 2020 DUBLIN, Ireland and TREVOSE, Pa., July 01, 2020 (GLOBE NEWSWIRE) -- Strongbrid...
Read more
June 30, 2020

Oncopeptides announces leadership changes: Jakob Lindberg assumes a new role as CSO, and Marty J Duvall is appointed CEO

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Ch...
Read more
June 30, 2020

Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal

Preliminary data indicate extensive and rapid absorption of OX125 across all formulations Positive results underline the applicability of Orexo’s novel intranasal drug d...
Read more
June 30, 2020

Oncopeptides submits a New Drug Application to the FDA for accelerated approval of melflufen in triple-class refractory multiple myeloma patients

STOCKHOLM — June 30, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company submits a New Drug Application (NDA) to the U.S. Food and Dr...
Read more
June 30, 2020

Nordic Nanovector to amend PARADIGME trial protocol to expand eligible patient population

Oslo, Norway, 30 June 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will amend the trial protocol for its PARADIGME trial to broaden the inclusion criteria ...
Read more